Document is current
Any future updates will be listed below
-
Authors
Armstrong, Andrew J. https://orcid.org/0000-0001-7012-1754
Taylor, Amy
Haffner, Michael C.
Abida, Wassim
Bryce, Alan H.
Karsh, Lawrence I.
Tagawa, Scott T. https://orcid.org/0000-0003-2777-8587
Twardowski, Przemyslaw
Serritella, Anthony V. https://orcid.org/0009-0006-9887-3054
Lang, Joshua M. https://orcid.org/0000-0002-0943-8872
- License Information
-
More Information
Article History
Received: 25 June 2024
Revised: 8 August 2024
Accepted: 20 September 2024
First Online: 1 October 2024
Competing interests
: There are no competing financial interests in relation to the work described. Below is a list of the authors total disclosures, none of which compete with this manuscript. AJA: Research support (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, Novartis. Consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Forma, Celgene, Myovant, Exelixis, GoodRx, Novartis, Medscape, MJH, Z Alpha, Telix. AT: Reports no relevant disclosures. MCH: MCH served as a paid consultant/received honoraria from Pfizer and has received research funding from Merck, Novartis, Genentech, Promicell and Bristol Myers Squibb. WA: WA is partially funded by NIH/NCI Cancer Center Support Grant P30-CA008748 and the Prostate Cancer Foundation. WA received speaking honoraria from Roche, Pfizer, Medscape, Aptitude Health, Clinical Education Alliance, touchIME and Onclive/MJH Life Sciences, consulting fees from Clovis Oncology, Janssen, ORIC Pharmaceuticals, Daiichi Sankyo, MOMA Therapeutics, Laekna Therapeutics and AstraZeneca, and Research Funding (to his institution) from AstraZeneca, Zenith Epigenetics, Clovis Oncology, ORIC Pharmaceuticals, Epizyme/Ipsen, Transthera, Merus, and Nuvation Bio. AHB: Advisory boards or travel support from Merck, Bayer, Pfizer, Astellas, Johnson and Johnson, Lantheus, Astra Zeneca, Novartis, Moma Therapeutics. Past research support (to Mayo Clinic) Johnson and Johnson. LIK: LIK owns stock in Swan Valley Medical, has received honoraria from Astellas, AstraZeneca, Abbvie, Bayer, Dendreon, Janssen, Merck, Myovant, Pfizer, and Sanofi, has received financial compensation as a paid consultant/advisor to Astellas, Astra-Zeneca, Abbvie, Bayer, Bristol Myers Squibb, Bayer, enGene, Ferring, Dendreon, Janssen, Merck, Myovant, Pfizer, and Sanofi, and has received financial compensation to participate in speakers bureaus for Astellas, Astra-Zeneca, Bayer, Dendreon, Janssen, Merck, Myovant, and Pfizer. He has received institutional funding from Janssen Bayer, Bristol Myers Squibb, Dendreon,E pizyme, Astellas, Pfizer, AstraZeneca, Merck, Myovant, BioExcel, Vaxiion, KDx, ImmunisAI/Oncocell,. FKD, Nucleix and Cleveland Diagnostics. STT: Research funding (to institution): Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma, Ambrx, Clarity. Honoraria for consulting: Sanofi, Medivation, Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth, AIkido Pharma, Gilead, Telix Pharma, Convergent Therapeutics, EMD Serono, Myovant, Merck, Daiichi Sankyo, TransThera, Regeneron, Ambrx, Boston Scientific. PT: Consulting and Speaker Bureaus: Astellas, Pfizer, Astra Zeneca, Janssen, Bayer, BMS, Merck, Aveo. AVS: 2023 ASCO Young Investigator Award. JML: Consulting for Pfizer, Janssen, Macrogenics, Foundation Medicine, Gilead, Arvinas, Astellas, Cytogen, Seattle Genetics.
